A human Lyme disease vaccine: two steps forward on the path to prevention
Lyme disease has expanded over the past two decades in both incidence and geographic footprint and is anticipated to continue to increase in the future due to changing climate and human encroachment into wildlife areas. VLA15 is currently in the last stage of clinical development, and if found to be safe and efficacious, may offer an important prophylactic modality for prevention of Lyme disease.
Authors
- Erik Lamberth (ORCID: https://orcid.org/0000-0002-0743-4595)
- James H. Stark (ORCID: https://orcid.org/0000-0002-0728-876X)
- Raphael Simon (ORCID: https://orcid.org/0000-0002-4136-0948)
- Julie M. Skinner (ORCID: https://orcid.org/0000-0003-4522-0472)
Institutions
- Pfizer (United Kingdom) (GB)
Publication Details
- Journal
- Expert Review of Vaccines
- Published
- 2025-12-22
- DOI
- https://doi.org/10.1080/14760584.2025.2607482
- Citations
- 1
- Primary Topic
- Vector-borne infectious diseases
- Type
- article
- Field-Weighted Citation Impact
- 2.05